Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer

被引:20
作者
Galal, K. M. [1 ,2 ]
Khaled, Z. [2 ,3 ]
Mourad, Abdel Monem M. [2 ,4 ]
机构
[1] Cairo Univ, Radiotherapy & Oncol Ctr NEMROCK, Cairo, Egypt
[2] Saudi German Hosp, Ctr Oncol, Riyadh, Saudi Arabia
[3] Tanta Univ, Dept Internal Med, Tanta, Egypt
[4] Assiut Univ, Dept Radiol, Assiut, Egypt
关键词
K-ras; cetuximab; sorafenib; metastatic colorectal carcinoma; K-RAS MUTATIONS; PHASE-II; KINASE; EGFR; PANITUMUMAB; EXPRESSION; KRAS; DISTRIBUTIONS; IRINOTECAN; INHIBITOR;
D O I
10.4103/0019-509X.75825
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: The relationship of epidermal growth factor receptors (EGFR) pathway, such as PI3K, K-ras, and B-raf, with response to EGFR-targeted antibodies is less well studied. AIM: To assess sorafenib with cetuximab in treating metastatic colorectal cancer. SETTINGS AND DESIGN: Thirty-five patients with metastatic colorectal cancer were randomized to receive cetuximab with or without oral sorafenib. PATIENTS AND METHODS: Patients received cetuximab IV weekly for four weeks and oral sorafenib twice daily on days 1 - 28, with recycling every four weeks. The primary end point was the response rate (partial and complete), while the secondary end points were the adverse effects, time to progression and overall survival. STATISTICAL ANALYSIS was made using the Statistical Product and Service Solutions, using SPSS 10.0, with estimation of both time to progression and overall survival time by the Kaplan-Meier method and comparing the two groups with the use of a log-rank test. RESULTS: Partial response was higher in cetuximab-sorafenib (EN), which constituted 33.3% compared to 17.6% in the cetuximab group (P = 0.44). Progression-free survival had a statistically higher significant difference in wild K-ras compared to mutant K-ras cases (P = .0001). Median overall survival was seven and five months in the (EN) and (E) groups respectively (P = 0.49). CONCLUSION: K-ras and B-raf was a predictor of response, so genotyping of tumors was needed for defining the patient population that was likely to benefit from the targeted therapy. A combination of therapy that simultaneously targets K-ras and B-raf could be a useful approach to increase the number of patients who may benefit from anti-EGFR therapy.
引用
收藏
页码:47 / 54
页数:8
相关论文
共 50 条
[21]   Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer [J].
Fakih, M. ;
Wong, R. .
CURRENT ONCOLOGY, 2010, 17 :S3-S17
[22]   TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy [J].
Oden-Gangloff, A. ;
Di Fiore, F. ;
Bibeau, F. ;
Lamy, A. ;
Bougeard, G. ;
Charbonnier, F. ;
Blanchard, F. ;
Tougeron, D. ;
Ychou, M. ;
Boissiere, F. ;
Le Pessot, F. ;
Sabourin, J-C ;
Tuech, J-J ;
Michel, P. ;
Frebourg, T. .
BRITISH JOURNAL OF CANCER, 2009, 100 (08) :1330-1335
[23]   Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations [J].
Ibrahim, Ezzeldin M. ;
Zekri, Jamal M. ;
Bin Sadiq, Bakr M. .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2010, 25 (06) :713-721
[24]   How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer? [J].
Lindsay, Colin R. ;
Roxburgh, Patricia ;
Graham, Janet .
FUTURE ONCOLOGY, 2013, 9 (06) :825-829
[25]   Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? [J].
Santini, D. ;
Vincenzi, B. ;
Addeo, R. ;
Garufi, C. ;
Masi, G. ;
Scartozzi, M. ;
Mancuso, A. ;
Frezza, A. M. ;
Venditti, O. ;
Imperatori, M. ;
Schiavon, G. ;
Bronte, G. ;
Cicero, G. ;
Recine, F. ;
Maiello, E. ;
Cascinu, S. ;
Russo, A. ;
Falcone, A. ;
Tonini, G. .
ANNALS OF ONCOLOGY, 2012, 23 (09) :2313-2318
[26]   Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy [J].
Di Fiore, F. ;
Blanchard, F. ;
Charbonnier, F. ;
Le Pessot, F. ;
Lamy, A. ;
Galais, M. P. ;
Bastit, L. ;
Killian, A. ;
Sesboue, R. ;
Tuech, J. J. ;
Queuniet, A. M. ;
Paillot, B. ;
Sabourin, J. C. ;
Michot, F. ;
Michel, P. ;
Frebourg, T. .
BRITISH JOURNAL OF CANCER, 2007, 96 (08) :1166-1169
[27]   The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment [J].
Holubec, Lubos ;
Polivka, Jiri, Jr. ;
Safanda, Martin ;
Karas, Michal ;
Liska, Vaclav .
ANTICANCER RESEARCH, 2016, 36 (09) :4421-4426
[28]   Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer [J].
Peng, Ke ;
Liu, Ruiqi ;
Yu, Yiyi ;
Liang, Li ;
Yu, Shan ;
Xu, Xiaojing ;
Liu, Tianshu .
BIOMEDICINE & PHARMACOTHERAPY, 2018, 97 :1138-1146
[29]   Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer [J].
Tsoukalas, N. ;
Tzovaras, A. A. ;
Tolia, M. ;
Kostakis, I. D. ;
Papakostidi, A. ;
Pistamaltzian, N. ;
Ardavanis, A. .
JOURNAL OF BUON, 2012, 17 (01) :73-78
[30]   Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies [J].
Qiu, Li-Xin ;
Mao, Chen ;
Zhang, Jian ;
Zhu, Xiao-Dong ;
Liao, Ru-Yan ;
Xue, Kai ;
Li, Jin ;
Chen, Qing .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (15) :2781-2787